First-line non–anthracycline-based chemotherapy for extranodal nasal-type NK/T-cell lymphoma: a retrospective analysis from the CLCG
Shu-Nan Qi,Yong Yang,Yu-Qin Song,Ying Wang,Xia He,Chen Hu,Li-Ling Zhang,Gang Wu,Bao-Lin Qu,Li-Ting Qian,Xiao-Rong Hou,Fu-Quan Zhang,Xue-Ying Qiao,Hua Wang,Gao-Feng Li,Hui-Qiang Huang,Yu-Jing Zhang,Yuan Zhu,Jian-Zhong Cao,Jun-Xin Wu,Tao Wu,Su-Yu Zhu,Mei Shi,Li-Ming Xu,Zhi-Yong Yuan,Hang Su,Jun Zhu,Ye-Xiong Li
DOI: https://doi.org/10.1182/bloodadvances.2020001852
IF: 7.642
2020-07-13
Blood Advances
Abstract:Abstract The present study investigated the survival benefit of non–anthracycline (ANT)-based vs ANT-based regimens in a large-scale, real-world cohort of patients with extranodal natural killer (NK)/T-cell lymphoma, nasal type (ENKTCL). Within the China Lymphoma Collaborative Group (CLCG) database (2000-2015), we identified 2560 newly diagnosed patients who received chemotherapy with or without radiotherapy. Propensity score matching (PSM) and multivariable analyses were used to compare overall survival (OS) and progression-free survival (PFS) between the 2 chemotherapy regimens. We explored the survival benefit of non–ANT-based regimens in patients with different treatments in early-stage disease and in risk-stratified subgroups. Non–ANT-based regimens significantly improved survivals compared with ANT-based regimens. The 5-year OS and PFS were 68.9% and 59.5% for non–ANT-based regimens compared with 57.5% and 44.5% for ANT-based regimens in the entire cohort. The clinical advantage of non–ANT-based regimens was substantial across the subgroups examined, regardless of stage and risk-stratified subgroup, and remained significant in early-stage patients who received radiotherapy. The survival benefits of non–ANT-based regimens were consistent after adjustment using multivariable and PSM analyses. These findings provide additional evidence supporting non–ANT-based regimens as a first-line treatment of patients with ENKTCL.
hematology